Biohit Oyj B (HE:BIOBV) — Market Cap & Net Worth
Market Cap & Net Worth: Biohit Oyj B (BIOBV)
Biohit Oyj B (HE:BIOBV) has a market capitalization of $35.29 Million (€30.19 Million) as of September 8, 2026. Listed on the HE stock exchange, this Finland-based company holds position #23319 globally and #118 in its home market, demonstrating a -5.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biohit Oyj B's stock price €2.47 by its total outstanding shares 12222093 (12.22 Million). Also see Biohit Oyj B asset portfolio for a full breakdown of the balance sheet.
Biohit Oyj B Market Cap History: 2015 to 2026
Biohit Oyj B's market capitalization history from 2015 to 2026. Data shows change from $80.16 Million to $35.29 Million (-7.57% CAGR). Also see cash flow conversion of Biohit Oyj B for how efficiently the company converts equity into cash flow.
Biohit Oyj B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biohit Oyj B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BIOBV live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.36x
Biohit Oyj B's market cap is 3.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
19.53x
Biohit Oyj B's market cap is 19.53 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $86.45 Million | $8.20 Million | -$3.29 Million | 10.55x | N/A |
| 2017 | $53.87 Million | $8.98 Million | $6.14 Million | 6.00x | 8.77x |
| 2018 | $42.30 Million | $9.93 Million | -$2.14 Million | 4.26x | N/A |
| 2019 | $48.01 Million | $10.05 Million | -$1.42 Million | 4.78x | N/A |
| 2020 | $35.44 Million | $7.12 Million | -$3.31 Million | 4.97x | N/A |
| 2021 | $26.22 Million | $9.36 Million | -$1.50 Million | 2.80x | N/A |
| 2022 | $22.43 Million | $10.95 Million | $601.00K | 2.05x | 37.33x |
| 2023 | $26.93 Million | $13.08 Million | $1.85 Million | 2.06x | 14.55x |
| 2024 | $32.72 Million | $14.30 Million | $2.60 Million | 2.29x | 12.59x |
| 2025 | $52.73 Million | $15.70 Million | $2.70 Million | 3.36x | 19.53x |
Competitor Companies of BIOBV by Market Capitalization
Companies near Biohit Oyj B in the global market cap rankings as of September 8, 2026. Review BIOBV intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Biohit Oyj B by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #115 globally with a market cap of $188.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #214 globally with a market cap of $116.27 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #231 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #244 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #115 | Abbott Laboratories | NYSE:ABT | $188.37 Billion | $108.33 |
| #214 | Stryker Corporation | NYSE:SYK | $116.27 Billion | $303.13 |
| #231 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $94.17 |
| #244 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Biohit Oyj B Historical Marketcap From 2015 to 2026
Between 2015 and today, Biohit Oyj B's market cap moved from $80.16 Million to $ 35.29 Million, with a yearly change of -7.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €35.29 Million | -33.06% |
| 2025 | €52.73 Million | +61.14% |
| 2024 | €32.72 Million | +21.49% |
| 2023 | €26.93 Million | +20.06% |
| 2022 | €22.43 Million | -14.44% |
| 2021 | €26.22 Million | -26.01% |
| 2020 | €35.44 Million | -26.19% |
| 2019 | €48.01 Million | +13.51% |
| 2018 | €42.30 Million | -21.49% |
| 2017 | €53.87 Million | -37.69% |
| 2016 | €86.45 Million | +7.84% |
| 2015 | €80.16 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 8th, 2026 the market cap of Biohit Oyj B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.29 Million USD |
| MoneyControl | $35.29 Million USD |
| MarketWatch | $35.29 Million USD |
| marketcap.company | $35.29 Million USD |
| Reuters | $35.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more